{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:24:18Z","timestamp":1790846658097,"version":"4.1.0"},"reference-count":21,"publisher":"American Psychiatric Association Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PS"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1176\/appi.ps.55.3.290","type":"journal-article","created":{"date-parts":[[2004,3,4]],"date-time":"2004-03-04T18:58:02Z","timestamp":1078426682000},"page":"290-294","source":"Crossref","is-referenced-by-count":86,"title":["Adjunctive Divalproex and Hostility Among Patients With Schizophrenia Receiving Olanzapine or Risperidone"],"prefix":"10.1176","volume":"55","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa D.","family":"Kochan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R5531141","doi-asserted-by":"crossref","unstructured":"Czobor P, Volavka J, Meibach RC: Effect of risperidone on hostility in schizophrenia. Journal Clinical Psychopharmacology 15:243\u2013249, 1995","DOI":"10.1097\/00004714-199508000-00002"},{"key":"R5531142","doi-asserted-by":"crossref","unstructured":"Kay SR, Opler LA, Lindenmayer JP: The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. British Journal of Psychiatry 155(suppl):59\u201365, 1989","DOI":"10.1192\/S0007125000291514"},{"key":"R5531143","doi-asserted-by":"crossref","unstructured":"Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 151:825\u2013835, 1994","DOI":"10.1176\/ajp.151.6.825"},{"key":"R5531144","unstructured":"Buckley PF, Ibrahim ZY, Singer B, et al: Aggression and schizophrenia: efficacy of risperidone. Journal of the American Academy of Psychiatry and the Law 25:173\u2013181, 1997"},{"key":"R5531145","unstructured":"Beck NC, Greenfield SR, Gotham H, et al: Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. Journal of the American Academy of Psychiatry and the Law 25:461\u2013468, 1997"},{"key":"R5531146","unstructured":"Kinon BJ, Roychowdhury SM, Milton DR, et al: Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. Journal of Clinical Psychiatry 62(suppl 2):17\u201321, 2001"},{"key":"R5531147","doi-asserted-by":"crossref","unstructured":"Citrome L, Volavka J, Czobor P, et al: Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility in patients with schizophrenia and schizoaffective disorder. Psychiatric Services 52:1510\u20131514, 2001","DOI":"10.1176\/appi.ps.52.11.1510"},{"key":"R5531148","doi-asserted-by":"crossref","unstructured":"Citrome L: Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. Journal of Pharmacy Technology 11:55\u201359, 1995","DOI":"10.1177\/875512259501100210"},{"key":"R5531149","unstructured":"McEvoy JP, Scheifler PL, Frances A: The Expert Consensus Guideline Series: treatment of schizophrenia 1999. Journal of Clinical Psychiatry 60(suppl 11):43, 1999"},{"key":"R55311410","doi-asserted-by":"crossref","unstructured":"Citrome L, Levine J, Allingham B: Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatric Services 51:634\u2013638, 2000","DOI":"10.1176\/appi.ps.51.5.634"},{"key":"R55311411","doi-asserted-by":"crossref","unstructured":"Citrome L, Jaffe A, Levine J: Use of mood stabilizers among patients with schizophrenia, 1994\u20132001. Psychiatric Services 53:1212, 2002","DOI":"10.1176\/appi.ps.53.10.1212"},{"key":"R55311412","unstructured":"Morinigo A, Martin J, Gonzalez S, et al: Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside Journal of Clinical Psychiatry 11:199\u2013207, 1989"},{"key":"R55311413","doi-asserted-by":"crossref","unstructured":"Wassef A, Watson D, Morrison P, et al: Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. Journal of Clinical Psychopharmacology 9:45\u201348, 1989","DOI":"10.1097\/00004714-198902000-00010"},{"key":"R55311414","unstructured":"Afaq I, Riaz J, Sedky K, et al: Divalproex as a calmative adjunct for aggressive schizophrenic patients. Journal of the Kentucky Medical Association 100(1):17\u201322, 2002"},{"key":"R55311415","doi-asserted-by":"crossref","unstructured":"Littrell KH, Petty RG, Hilligoss NM, et al: Valproate for hostility in schizophrenia patients. Journal of Clinical Psychiatry 65:134, 2004","DOI":"10.4088\/JCP.v65n0122d"},{"key":"R55311416","doi-asserted-by":"crossref","unstructured":"Lindenmayer JP, Kotsaftis A: Use of sodium valproate in violent and aggressive behaviors: a critical review. Journal of Clinical Psychiatry 61:123\u2013128, 2000","DOI":"10.4088\/JCP.v61n0207"},{"key":"R55311417","doi-asserted-by":"crossref","unstructured":"Casey DE, Daniel DG, Wassef AA, et al: Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28:182\u2013192, 2003","DOI":"10.1038\/sj.npp.1300023"},{"key":"R55311419","doi-asserted-by":"crossref","unstructured":"Lindenmayer JP, Bernstein-Hyman R, Grochowski S, et al: Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology 28:22\u201331, 1995","DOI":"10.1159\/000284896"},{"key":"R55311420","doi-asserted-by":"crossref","unstructured":"Baker RW, Kinon BJ, Maguire GA, et al: Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. Journal of Clinical Psychopharmacology 23:342\u2013348, 2003","DOI":"10.1097\/01.jcp.0000085406.08426.a8"},{"key":"R55311421","doi-asserted-by":"crossref","unstructured":"Binder RL, McNiel DE: Effects of diagnosis and context on dangerousness. American Journal of Psychiatry 145:728\u2013732, 1988","DOI":"10.1176\/ajp.145.6.728"},{"key":"R55311423","unstructured":"Citrome L: Schizophrenia and valproate. Psychopharmacology Bulletin, 37(3 suppl 2):74\u201388, 2003"}],"container-title":["Psychiatric Services"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ps.55.3.290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T12:17:06Z","timestamp":1722169026000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ps.55.3.290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1176\/appi.ps.55.3.290"],"URL":"https:\/\/doi.org\/10.1176\/appi.ps.55.3.290","relation":{},"ISSN":["1075-2730","1557-9700"],"issn-type":[{"value":"1075-2730","type":"print"},{"value":"1557-9700","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}